This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

11 Apr 2011

Bayer & Regeneron Start Phase 3 Clinical Program in Diabetic Macular Edema

The two companies are extending their development program for VEGF Trap-Eye in DME after promising results in the global Phase 2 DME program.

Bayer HealthCare and Regeneron Pharmaceuticals, Inc. have launched the first of two Phase 3 clinical trials to evaluate the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME).  


The first Phase 3 trial in DME, named VIVID-DME, is being led by Bayer HealthCare and has started in Australia. The trial will also be conducted in Europe and Japan. A second study led by Regeneron, named VISTA-DME, is expected to begin later in 2011 in the U.S, Canada, and other countries.


The Phase 3 program in DME expands the companies’ global development collaboration for VEGF

Related News